Concentration changes in gemcitabine and its metabolites after hyperthermia in pancreatic cancer cells assessed using RP-HPLC

BACKGROUND: Gemcitabine (2′,2′-difluoro-2′-deoxycytidine;dFdC) is a first-line chemotherapy drug for pancreatic cancer. Recently, a synergistic anti-tumor treatment of dFdC and hyperthermia has achieved good clinical results, but there are few reports on the molecular mechanism influenced by hyperth...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, HB, Lu, L, Xie, L, Yang, JF, Zhang, XF, Ma, SL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521548/
https://www.ncbi.nlm.nih.gov/pubmed/31131010
http://dx.doi.org/10.1186/s11658-019-0153-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521548/
https://www.ncbi.nlm.nih.gov/pubmed/31131010
http://dx.doi.org/10.1186/s11658-019-0153-1

Ejemplares similares